These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32694298)

  • 1. Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer.
    Leiker AJ; Wang CJ; Sanford NN; Aguilera TA; Karri S; Beg MS; Kazmi SA; Olson C; Matthews JA; Abdelnaby A; Meyer JJ; Folkert MR
    Am J Clin Oncol; 2020 Oct; 43(10):701-708. PubMed ID: 32694298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
    White EC; Goldman K; Aleshin A; Lien WW; Rao AR
    Radiother Oncol; 2015 Nov; 117(2):240-5. PubMed ID: 26347494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
    Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
    Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Toxicity and Treatment Outcomes in HIV-positive Versus HIV-negative Patients With Squamous Cell Carcinoma of the Anal Canal.
    White EC; Khodayari B; Erickson KT; Lien WW; Hwang-Graziano J; Rao AR
    Am J Clin Oncol; 2017 Aug; 40(4):386-392. PubMed ID: 25513996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
    Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM
    Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.
    Goodman KA; Julie D; Cercek A; Cambridge L; Woo KM; Zhang Z; Wu AJ; Reidy DL; Segal NH; Stadler ZK; Saltz LB
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1087-1095. PubMed ID: 28721892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
    Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
    Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
    Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
    Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Toxicity of (Chemo)Radiation Therapy in HIV+ Patients with Squamous Cell Anal Cancer, a Subgroup Analysis of the National Multicenter Cohort FFCD-ANABASE.
    Evin C; Quéro L; Le Malicot K; Blanchet-Deverly S; Evesque L; Buchalet C; Lemanski C; Hamed NB; Rivin Del Campo E; Bauwens L; Pommier P; Lièvre A; Gouriou C; Tougeron D; Macé V; Sergent G; Diaz O; Zucman D; Mornex F; Locher C; De la Rochefordière A; Vendrely V; Huguet F
    Int J Radiat Oncol Biol Phys; 2024 Nov; 120(3):708-719. PubMed ID: 38912999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.
    Wo JY; Plastaras JP; Metz JM; Jiang W; Yeap BY; Drapek LC; Adams J; Baglini C; Ryan DP; Murphy JE; Parikh AR; Allen JN; Clark JW; Blaszkowsky LS; DeLaney TF; Ben-Josef E; Hong TS
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):90-95. PubMed ID: 31128146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
    Hauerstock D; Ennis RD; Grossbard M; Evans A
    Clin Colorectal Cancer; 2010 Oct; 9(4):238-42. PubMed ID: 20920996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy.
    Ghareeb A; Paramasevon K; Mokool P; van der Voet H; Jha M
    Ann R Coll Surg Engl; 2019 Mar; 101(3):168-175. PubMed ID: 30482037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of anal cancer patients at the Ottawa hospital.
    Abunassar M; Reinders J; Jonker DJ; Asmis T
    Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anal cancer chemoirradiation with curative intent - a single institution experience.
    Oblak I; Petric P; Anderluh F; Velenik V; Hudej R; Fras AP
    Neoplasma; 2009; 56(2):150-5. PubMed ID: 19239330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy.
    Joseph K; Al Habsi Z; Abraham A; Elangovan A; Ghosh S; Pham T; Shreekumar D; Ramji Z; Paulson K; Tankel K; Usmani N; Severin D; Schiller D; Wong C; Mulder K; Karachiwala H; Doll C; King K; Nijjar T
    Radiother Oncol; 2024 Jul; 196():110219. PubMed ID: 38479443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
    Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
    Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
    Voong KR; Rashid A; Crane CH; Minsky BD; Krishnan S; Yao JC; Wolff RA; Skibber JM; Feig BW; Chang GJ; Das P
    Am J Clin Oncol; 2017 Dec; 40(6):555-560. PubMed ID: 26237193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
    Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
    Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.